Panobinostat to revert bortezomib resistance

Abstract

In this issue of Blood, Richardson et al present convincing results demonstrating that panobinostat, an oral pan-deacetylase inhibitor, in combination with bortezomib and dexamethasone, can recapture responses in bortezomib-refractory multiple myeloma (MM).1 © 2013 by The American Society of Hematology.